DEPARTMENT : Nuclear Medicine
PRIMARY LOCATION : Istanbul Florence Nightingale Hospital
LANGUAGES : English, Turkish
Expert Opinion
Get A Second Opinion
The medical second opinion will be presented to you within 48 hours.
DEPARTMENT : Nuclear Medicine
PRIMARY LOCATION : Istanbul Florence Nightingale Hospital
LANGUAGES : English, Turkish
Present
Istanbul Florence Nigthingale Hospital
Nuclear Medicine Physician2022-2025
Sisli Etfal Education and Research Hospital
Nuclear Medicine Physician2022-2023
Queen Elizabeth Hospital, University of Birmingham
Senior Clinical Fellow2017-2022
Sisli Etfal Education and Research Hospital
Nuclear Medicine Physician2016-2017
Erasmus Medical University, Rotterdam
Clinical Research Fellow2013-2016
Bagcilar Education and Research Hospital
Nuclear Medicine Physician
2009-2013
Istanbul University, Cerrahpasa Medical Faculty Nuclear Medicine Department
Assistant Doctor2000 – 2006
Istanbul University, Cerrahpasa Medical Faculty2014-2014
Peter MacCallum Cancer Centre, Melbourne
Observer Nuclear Medicine Physician2010-2010
Netherlands Cancer Institute, Amsterdam, Netherlands
Observer Assistant Doctor2007-2008
Istanbul University, Cerrahpasa Medical Faculty
Assistant Doctor2008-2009
Puturge Public Hospital, Malatya
• Ekmekcioglu O, Hughes S, Fendler WP, Verzijlbergen F, Kong G, Hofman MS. May the Nuclear Medicine be with you! Neuroendocrine tumours and the return of nuclear medicine. Eur J Nucl Med Mol Imaging. 2024 Aug 19. doi: 10.1007/s00259-024-06877-6. Epub ahead of print. • Ekmekcioglu O, Albert NL, Heinrich K, Tolboom N, Van Weehaeghe D, Traub-Weidinger T, Atay LO, Garibotto V, Morbelli S. Neurological Disorders and Women’s Health: Contribution of Molecular Neuroimaging Techniques. Semin Nucl Med. 2024 Mar;54(2):237-246. doi: 10.1053/j.semnuclmed.2024.01.010. Epub 2024 Feb 15. PMID: 38365546.
• Kostek M, Kostek H, Unlu MT, Caliskan O, Cakir Y, Sengul Z, Ekmekcioglu O, Kafi M, Ozel A, Aygun N, Uludag M. (2025). Deciding on Fine Needle Aspiration Biopsy in Thyroid Incidentalomas in FDG-PET/CT: Should Ultrasonographic Evaluation or FDG Uptake Be in the Foreground? Sisli Etfal Hastanesi tip bulteni, 59,20–27. https://doi.org/10.14744/SEMB.2025.49140
• Akçay, K., Beydağı, G., Şahin, O. E., Akyel, R., Akgün, E., Ekmekçioğlu, Ö., Alan Selçuk, N., Toklu, T., Doğan Ekici, A. I., Kapran, K., & Kabasakal, L. (2025). Improved Accuracy and Reliability of PRIMARY Scoring Using Delayed [68Ga] Ga-PSMA PET/CT Imaging. Molecular imaging and radionuclide therapy, 34(1), 1–9. https://doi.org/10.4274/mirt.galenos.2025.16023 • Eisses B, van Geel JJL, Brouwers AH, Bensch F, Elias SG, Kuip EJM, Jager A, van der Vegt B, Lub-de Hooge MN, Emmering J, Arens AIJ, Zwezerijnen GJC, Vugts DJ, Menke-van der Houven van Oordt CW, de Vries EGE, Schröder CP, on behalf of the IMPACT-MBC consortium. Whole-Body HER2 Heterogeneity Identified on HER2 PET in HER2-Negative, – Low, and -Positive Metastatic Breast Cancer. J Nucl Med. 2024 Oct 1;65(10):1540-1547. doi: 10.2967/jnumed.124.267636. PMID: 39237347.
• Ozen A, Sayin T, Kandemir O, et al. Comparison between 18F-FDG PET/CT and diffusion- weighted imaging in detection of invasive ductal breast carcinoma. Asia Ocean J Nucl Med Biol. 2024;12(1):11-20. doi:10.22038/AOJNMB.2023.70534.1493
• Gürez C, Özen A, Ekmekçioğlu Ö. How Radioactive Iodine Treatment Affects the Retina. World J Nucl Med. 2023;22(4):257-260. Published 2023 Dec 4. doi:10.1055/s-0043- 1774419
• Ekmekcioglu O, Terry SYA, Morbelli S, et al. Superfluous, controversial and luxury issues in nuclear medicine. Eur J Nucl Med Mol Imaging. 2023;50(9):2582-2587. doi:10.1007/s00259- 023-06228-x
• Ekmekcioglu O, Erdem U, Arican P, Ozvar H, Bostanci O. The value of radioembolisation therapy on metastatic liver tumours – a single centre experience. Der Wert der Radioembolisationstherapie bei metastasierten Lebertumoren – eine Erfahrung aus einem einzigen Zentrum. Nuklearmedizin. 2023;62(3):214-219. doi:10.1055/a-2026-0851
• Ekmekçioğlu Ö, Battal M, Bostancı Ö, & Yılmaz Özgüven B. (2023). The Impact of Metabolic18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Parameters on the Prognosis of Resectable Pancreatic Adenocarcinoma. Molecular imaging and radionuclide therapy, 32(1), 35–41. https://doi.org/10.4274/mirt.galenos.2022.93823
• Verger A, Barthel H, Tolboom N, Fraioli F, Cecchin D, Albert NL, van Berckel B, Boellaard R, Brendel M, Ekmekcioglu O, Semah F, Traub-Weidinger T, van de Weehaeghe D, Morbelli S, Guedj E. 2-[18F]-FDG PET for imaging brain involvement in patients with long COVID: perspective of the EANM Neuroimaging Committee. Eur J Nucl Med Mol Imaging. 2022 Sep;49(11):3599-3606. doi: 10.1007/s00259-022-05913-7. PMID: 35840817; PMCID: PMC9286958.
• Ekmekcioglu O, Bakan S, Sönmezoğlu K. Mesenteric Panniculitis Appears as Metastatic Disease on 18F-FDG-PET/CT Scan. Mol Imaging Radionucl Ther. 2022 Jun 27;31(2):154-156. doi: 10.4274/mirt.galenos.2021.95914. PMID: 35771041; PMCID: PMC9246301.
• Evangelista L, Pietrzak A, Ekmekcioglu O, Ovcaricek PP, Ambrosini V, Balogova S, Cunha L, Eccles A, Garibotto V, Lewington V, Israel O, Kunikowska J. Gender issues in the nuclear medicine community: results from a survey promoted by the EANM Women Empowerment Task Force. Eur J Nucl Med Mol Imaging. 2022 Jun;49(7):2106-2112. doi: 10.1007/s00259- 022-05790-0.
• Ekmekcioglu O, Yavuzsan AH, Arican P, Kirecci SL. Is there a nonnegligible effect of maximum standardized uptake value in the staging and management of prostate cancer with 68Ga-prostate-specific membrane antigen positron emission tomography/computerized tomography imaging? A single-center experience. J Cancer Res Ther. 2021 Oct- Dec;17(6):1351-1357. doi: 10.4103/jcrt.JCRT_1223_20.
• Guedj E, Varrone A, Boellaard R, Albert NL, Barthel H, van Berckel B, Brendel M, Cecchin D, Ekmekcioglu O, Garibotto V, Lammertsma AA, Law I, Peñuelas I, Semah F, Traub- Weidinger T, van de Giessen E, Van Weehaeghe D, Morbelli S. EANM procedure guidelines for brain PET imaging using [18F]FDG, version 3. Eur J Nucl Med Mol Imaging. 2022 Jan;49(2):632-651. doi: 10.1007/s00259-021-05603-w. Epub 2021 Dec 9. Erratum in: Eur J Nucl Med Mol Imaging. 2022 Mar 7;:
• Ekmekcioglu O; Calis M. 18F-FDG PET/CT Imaging of an Extramedullary Solitary Plasmacytoma of the Maxillary Sinus; A Case Report. European Archives of Medical Research 2022-03-01 DOI: 10.4274/eamr.galenos.2022.59254
• Ekmekcioglu O. The Use of 18F-FDG PET/CT in Patients with Recurrent Differentiated Thyroid Cancer. Mol Imaging Radionucl Ther. 2021 Oct 15;30(3):137-143. doi: 10.4274/mirt.galenos.2021.02360.
• Ekmekcioglu O, Kaplan NB. The Utility of Ga-68 DOTA-TATE PET/CT on Clinical Management of Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET) European Archives of Medical Research 2022; 38, 132 10.4274/eamr.galenos.2021.41196
• Ekmekcioglu O; Arıcan P; Berk G. Therapeutic Approach to Metastatic Neuroendocrine Tumors of the Liver: The Radioembolization Nuclear Medicine Seminars 2021-11-01; DOI: 10.4274/nts.galenos.2021.0035
• Evangelista L, Ekmekcioglu O, Kunikowska J. Gender balance in the editorial board of nuclear medicine journals. Eur J Nucl Med Mol Imaging. 2021 Nov;48(12):3749-3750. doi: 10.1007/s00259-021-05491-0.
• Ekmekcioglu O, Evangelista L, Kunikowska J. Women in nuclear medicine. Eur J Nucl Med Mol Imaging. 2021 Aug;48(9):2678-2679. doi: 10.1007/s00259-021-05418-9. PMID: 34032864.
• Ekmekcioglu O, Tabakci ON, Bozdag NK, et al. Factors affecting the response to treatment and survival in hepatocellular carcinoma patients treated with transarterial radioembolisation: a single-centre experience. Eur J Gastroenterol Hepatol. 2021 Mar 12. doi: 10.1097/MEG.0000000000002117.
• Has Simsek D, Kuyumcu S, Karadogan S, Oflas M, Isik EG, Ozkan ZG, Paksoy N, Ekmekcioglu O, Ekenel M, Sanli Y. Can PSMA-based tumor burden predict response to docetaxel treatment in metastatic castration-resistant prostate cancer? Ann Nucl Med. 2021 Mar 30. doi: 10.1007/s12149-021-01610-x.
• Ekmekcioglu O, Sonmezoglu K. Fluorine-18 Fluorodeoxyglucose PET/CT Images of Hidradenitis Suppurativa Mimicking Metastasis in a Patient With Small Cell Lung Carcinoma. Cureus. 2020 Nov 29;12(11):e11770. doi: 10.7759/cureus.11770.
• Morbelli S, Ekmekcioglu O et al. COVID-19 and the brain: impact on nuclear medicine in neurology. Eur J Nucl Med Mol Imaging. 2020;47:2487-92
• Morbelli S, Esposito G, Arbizu J, et al. Ekmekcioglu O et al. EANM practice guideline/SNMMI procedure standard for dopaminergic imaging in Parkinsonian syndromes 1.0. Eur J Nucl Med Mol Imaging. 2020;47:1885-912.
• Ekmekcioglu O, Arican P, Mese S, Kaplan N, Kafi M, Simsek D, Ertürk MS.. PET/CT findings of a patient with cardiac metastases of subungual malign melanoma. MIRT-59251
• Ekmekcioglu O, Busstra M, Klass ND, Verzijlbergen F. Bridging the imaging gap: PSMA PET/CT has a high impact on treatment planning in prostate cancer patients with biochemical recurrence – a narrative review of literature. J Nucl Med. 2019 Mar 8. pii: jnumed.118.222885. doi: 10.2967/jnumed.118.222885.
• Ekmekcioglu, O. Research, Research, Otherwise we are lost!: J Nuc Med. 2018 Apr;59:719 • Morbelli S, Arbizu J, Booij J, Chen MK, Chetelat G, Cross DJ, Djekidel M, Drzezga A,
Ekmekcioglu O et al. The need of standardization and of large clinical studies in an emerging indication of [18F]FDG PET: the autoimmune encephalitis. Eur J Nucl Med Mol Imaging. 2017 Mar;44:353-357
• Zanotti-Fregonara P, Chastan M, Edet-Sanson A, Ekmekcioglu O, Erdogan EB, Hapdey S, Hindie E, Stabin MG. New fetal doses from 18FDG administered during pregnancy: standardization of dose calculations and estimations with voxel-based anthropomorphic phantoms. J Nucl Med. 2016 Nov;57:1760-1763
• Ozen A, Altinay S, Ekmekcioglu O et al. Dual-Time 18F-FDG PET/CT Imaging in Initial Locoregional Staging of Breast Carcinoma: Comparison with Conventional Imaging and Pathological Prognostic Factors. Indian J Surg, 2016. Oct;78:382-389
• Ozen A, Baştuğ E, Aşkaroğlu B, Ekmekcioglu O. The Rare Isolated Solitary Muscle Metastasis of Breast Carcinoma Confirmed by 18F-FDG PET/CT. J Clin Anal Med 2016;7: 557-9
• Ozen A, Sut P, Ekmekcioglu O et al. The metastasis of atypical carcinoid tumor in breast detected by 18F-FDG PET/CT. Sylwan. 2015 159(3);542-550
• Ekmekcioglu O, Zerizer I, Pilkington P et al. The Young EANM Committee survey. Eur J Nucl Med Mol Imaging. 2016:601-3
• Vatankulu B, Ekmekcioglu O, Aksoy SY et al. Assessment of treatment response with FDG PET/CT on a primary neuroendocrine tumor of vagina. Rev Esp Med Nucl Imagen Mol. 2016;35:143-4.
• Yilmaz S, Aliyev A, Ekmekcioglu O et al. Comparison of FDG and FDG-labeled leukocytes PET/CT in diagnosis of infection. Nuklearmedizine 2015;54:262-71.
• Ekmekcioglu O, Vatankulu B, Akyel R, Ozbayrak M, Sonmezoglu K. FDG-PET/CT imaging of an isolated recurrence in the eyelid of a patient with follicular lymphoma. Clin Nucl Med 2015;40:871-2
• Uzel EK, Ekmekcioglu O, Elicin O, Halac M, Uzel OE. Is FDG -PET-CT A Valuable Tool in Prediction of Persistent Disease in Head and Neck Cancer. Asian Pac J Cancer Prev. 2013;14:4847-51.
• Ekmekcioglu O, Aliyev A, Yilmaz S, Arslan E, Kaya R, Kocael P, Erkan ME, Halac M, Sonmezoglu K. Correlation of 18F-fluorodeoxyglucose uptake with histopathological prognostic factors in breast carcinoma. Nucl Med Commun. 2013;34:1055-67.
• Erdogan EB, Ekmekcioglu O, Vatankulu B, Ergül N, Demir M, Sonmezoglu K. An unknown pregnancy at term detected by a FDG-PET/CT study in a patient with Hodgkin’s lymphoma: A case report. Rev Esp Med Nucl Imagen Mol. 2015; 34:201-2
• Yilmaz S, Vatankulu B, Ekmekcioglu O, Sager S, Halac M. FDG and FDG-labelled leucocyte PET/CT in the imaging of prosthetic joint infection: response to Lazzeri et al. Eur J Nucl Med Mol Imaging. 2014 ;41:1813-4.
• Arslan E, Ekmekcioglu O, Gortan A et al. The value of FDG-PET/CT by using 3-dimensional stereotactic surface projection software analysis in the differential diagnosis of dementia. Turkish Journal of Medical Sciences. Turk J Med Sci. 2015;45:1149-58.